25 XP   0   0   10

BioNTech SE
Buy, Hold or Sell?

Let's analyze Biontech together

I guess you are interested in BioNTech SE. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of BioNTech SE. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about BioNTech SE

I send you an email if I find something interesting about BioNTech SE.

Quick analysis of Biontech (30 sec.)










What can you expect buying and holding a share of Biontech? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
26.1%

What is your share worth?

Current worth
$89.61
Expected worth in 1 year
$89.76
How sure are you?
73.9%

+ What do you gain per year?

Total Gains per Share
$0.15
Return On Investment
0.2%

For what price can you sell your share?

Current Price per Share
$79.86
Expected price per share
$0 - $113.04
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

1. Valuation of Biontech (5 min.)




Live pricePrice per Share (EOD)

$79.86

Intrinsic Value Per Share

$169.77 - $192.99

Total Value Per Share

$259.38 - $282.60

2. Growth of Biontech (5 min.)




Is Biontech growing?

Current yearPrevious yearGrowGrow %
How rich?$21.5b$20.4b$1.2b5.6%

How much money is Biontech making?

Current yearPrevious yearGrowGrow %
Making money$30.5m$1.6b-$1.6b-5,420.2%
Net Profit Margin-58.2%49.1%--

How much money comes from the company's main activities?

3. Financial Health of Biontech (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#3 / 966

Most Revenue
#18 / 966

Most Profit
#42 / 966

Most Efficient
#420 / 966
3rd party ad coffee SUPPORTERis ad-free.

What can you expect buying and holding a share of Biontech? (5 min.)

Welcome investor! Biontech's management wants to use your money to grow the business. In return you get a share of Biontech.

What can you expect buying and holding a share of Biontech?

First you should know what it really means to hold a share of Biontech. And how you can make/lose money.

Speculation

The Price per Share of Biontech is $79.86. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Biontech.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Biontech, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $89.61. Based on the TTM, the Book Value Change Per Share is $0.04 per quarter. Based on the YOY, the Book Value Change Per Share is $5.80 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Biontech.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.41-1.8%0.520.6%3.985.0%3.794.7%3.284.1%
Usd Book Value Change Per Share-0.91-1.1%0.040.0%5.807.3%4.215.3%3.904.9%
Usd Dividend Per Share0.000.0%0.000.0%0.530.7%0.410.5%0.360.4%
Usd Total Gains Per Share-0.91-1.1%0.040.0%6.347.9%4.625.8%4.255.3%
Usd Price Per Share92.25-103.59-139.69-115.87-100.75-
Price to Earnings Ratio-16.31-17.92-26.74-3.05-2.65-
Price-to-Total Gains Ratio-100.95--365.05-37.81--67.96--67.96-
Price to Book Ratio1.03-1.16-1.74-7.31-6.36-
Price-to-Total Gains Ratio-100.95--365.05-37.81--67.96--67.96-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share79.86
Number of shares12
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.41
Usd Book Value Change Per Share0.044.21
Usd Total Gains Per Share0.044.62
Gains per Quarter (12 shares)0.4455.42
Gains per Year (12 shares)1.76221.67
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
102-820202212
204-639404434
305-459606656
407-278808878
50909810101100
6011211812121322
7012413714141544
8014615716161766
9016817718181988
100181019620212210

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share3.01.00.075.0%11.01.00.091.7%13.07.00.065.0%13.010.00.056.5%13.010.00.056.5%
Book Value Change Per Share1.03.00.025.0%9.03.00.075.0%15.05.00.075.0%17.05.01.073.9%17.05.01.073.9%
Dividend per Share0.00.04.00.0%6.00.06.050.0%6.00.014.030.0%6.00.017.026.1%6.00.017.026.1%
Total Gains per Share1.03.00.025.0%9.03.00.075.0%15.05.00.075.0%17.05.01.073.9%17.05.01.073.9%
3rd party ad coffee SUPPORTERis ad-free.

Fundamentals of Biontech

About BioNTech SE

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac

Fundamental data was last updated by Penke on 2024-06-17 16:11:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is fair priced.
Based on how much money comes from the company's main activities, the company is cheap.
3rd party ad coffee SUPPORTERis ad-free.

1.1. Profitability of BioNTech SE.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Biontech earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Biontech to the Biotechnology industry mean.
  • A Net Profit Margin of -168.0% means that $-1.68 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of BioNTech SE:

  • The MRQ is -168.0%. The company is making a huge loss. -2
  • The TTM is -58.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-168.0%TTM-58.2%-109.8%
TTM-58.2%YOY49.1%-107.3%
TTM-58.2%5Y-43.9%-14.3%
5Y-43.9%10Y-50.0%+6.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-168.0%-168.0%+0.0%
TTM-58.2%-209.9%+151.7%
YOY49.1%-242.3%+291.4%
5Y-43.9%-401.7%+357.8%
10Y-50.0%-532.2%+482.2%
1.1.2. Return on Assets

Shows how efficient Biontech is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Biontech to the Biotechnology industry mean.
  • -1.4% Return on Assets means that Biontech generated $-0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of BioNTech SE:

  • The MRQ is -1.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is 0.1%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-1.4%TTM0.1%-1.5%
TTM0.1%YOY7.0%-6.9%
TTM0.1%5Y5.7%-5.5%
5Y5.7%10Y4.8%+0.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.4%-11.9%+10.5%
TTM0.1%-11.9%+12.0%
YOY7.0%-11.3%+18.3%
5Y5.7%-13.5%+19.2%
10Y4.8%-14.9%+19.7%
1.1.3. Return on Equity

Shows how efficient Biontech is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Biontech to the Biotechnology industry mean.
  • -1.6% Return on Equity means Biontech generated $-0.02 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of BioNTech SE:

  • The MRQ is -1.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is 0.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ-1.6%TTM0.1%-1.7%
TTM0.1%YOY8.4%-8.2%
TTM0.1%5Y8.1%-8.0%
5Y8.1%10Y6.9%+1.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-1.6%-14.2%+12.6%
TTM0.1%-15.7%+15.8%
YOY8.4%-14.3%+22.7%
5Y8.1%-19.2%+27.3%
10Y6.9%-19.7%+26.6%
3rd party ad coffee SUPPORTERis ad-free.

1.2. Operating Efficiency of BioNTech SE.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Biontech is operating .

  • Measures how much profit Biontech makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Biontech to the Biotechnology industry mean.
  • An Operating Margin of -174.4% means the company generated $-1.74  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of BioNTech SE:

  • The MRQ is -174.4%. The company is operating very inefficient. -2
  • The TTM is -92.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-174.4%TTM-92.7%-81.6%
TTM-92.7%YOY66.6%-159.3%
TTM-92.7%5Y-40.9%-51.8%
5Y-40.9%10Y-46.9%+6.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-174.4%-354.6%+180.2%
TTM-92.7%-225.9%+133.2%
YOY66.6%-252.2%+318.8%
5Y-40.9%-428.3%+387.4%
10Y-46.9%-531.1%+484.2%
1.2.2. Operating Ratio

Measures how efficient Biontech is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 3.70 means that the operating costs are $3.70 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of BioNTech SE:

  • The MRQ is 3.704. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.392. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.704TTM2.392+1.312
TTM2.392YOY0.354+2.038
TTM2.3925Y1.514+0.877
5Y1.51410Y1.568-0.054
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.7043.004+0.700
TTM2.3923.332-0.940
YOY0.3543.502-3.148
5Y1.5145.271-3.757
10Y1.5686.915-5.347
3rd party ad coffee SUPPORTERis ad-free.

1.3. Liquidity of BioNTech SE.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Biontech is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 11.38 means the company has $11.38 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of BioNTech SE:

  • The MRQ is 11.379. The company is very able to pay all its short-term debts. +2
  • The TTM is 10.437. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ11.379TTM10.437+0.942
TTM10.437YOY7.726+2.711
TTM10.4375Y5.755+4.682
5Y5.75510Y5.320+0.435
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.3793.767+7.612
TTM10.4374.000+6.437
YOY7.7264.905+2.821
5Y5.7555.883-0.128
10Y5.3206.286-0.966
1.3.2. Quick Ratio

Measures if Biontech is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Biontech to the Biotechnology industry mean.
  • A Quick Ratio of 15.12 means the company can pay off $15.12 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of BioNTech SE:

  • The MRQ is 15.119. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 12.200. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ15.119TTM12.200+2.920
TTM12.200YOY7.579+4.620
TTM12.2005Y6.061+6.138
5Y6.06110Y5.486+0.575
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.1193.054+12.065
TTM12.2003.506+8.694
YOY7.5794.756+2.823
5Y6.0615.757+0.304
10Y5.4866.338-0.852
3rd party ad coffee SUPPORTERis ad-free.

1.4. Solvency of BioNTech SE.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Biontech assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Biontech to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.10 means that Biontech assets are financed with 10.3% credit (debt) and the remaining percentage (100% - 10.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of BioNTech SE:

  • The MRQ is 0.103. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.108. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.103TTM0.108-0.005
TTM0.108YOY0.154-0.046
TTM0.1085Y0.276-0.168
5Y0.27610Y0.286-0.010
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1030.330-0.227
TTM0.1080.342-0.234
YOY0.1540.287-0.133
5Y0.2760.368-0.092
10Y0.2860.382-0.096
1.4.2. Debt to Equity Ratio

Measures if Biontech is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Biontech to the Biotechnology industry mean.
  • A Debt to Equity ratio of 11.5% means that company has $0.11 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of BioNTech SE:

  • The MRQ is 0.115. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.121. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.115TTM0.121-0.007
TTM0.121YOY0.185-0.064
TTM0.1215Y0.429-0.307
5Y0.42910Y0.474-0.045
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1150.365-0.250
TTM0.1210.415-0.294
YOY0.1850.370-0.185
5Y0.4290.443-0.014
10Y0.4740.476-0.002
3rd party ad coffee SUPPORTERis ad-free.

2. Market Valuation of BioNTech SE

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Biontech generates.

  • Above 15 is considered overpriced but always compare Biontech to the Biotechnology industry mean.
  • A PE ratio of -16.31 means the investor is paying $-16.31 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of BioNTech SE:

  • The EOD is -14.119. Based on the earnings, the company is expensive. -2
  • The MRQ is -16.309. Based on the earnings, the company is expensive. -2
  • The TTM is 17.925. Based on the earnings, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD-14.119MRQ-16.309+2.190
MRQ-16.309TTM17.925-34.234
TTM17.925YOY26.736-8.811
TTM17.9255Y3.045+14.880
5Y3.04510Y2.648+0.397
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-14.119-2.341-11.778
MRQ-16.309-2.997-13.312
TTM17.925-2.882+20.807
YOY26.736-3.553+30.289
5Y3.045-6.262+9.307
10Y2.648-6.288+8.936
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of BioNTech SE:

  • The EOD is -9.795. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.314. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 2.065. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD-9.795MRQ-11.314+1.520
MRQ-11.314TTM2.065-13.380
TTM2.065YOY1.717+0.348
TTM2.0655Y-17.043+19.109
5Y-17.04310Y-14.820-2.223
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.795-2.932-6.863
MRQ-11.314-3.739-7.575
TTM2.065-3.776+5.841
YOY1.717-4.917+6.634
5Y-17.043-7.942-9.101
10Y-14.820-8.503-6.317
3rd party ad coffee SUPPORTERis ad-free.
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Biontech is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.03 means the investor is paying $1.03 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of BioNTech SE:

  • The EOD is 0.891. Based on the equity, the company is cheap. +2
  • The MRQ is 1.029. Based on the equity, the company is underpriced. +1
  • The TTM is 1.155. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD0.891MRQ1.029-0.138
MRQ1.029TTM1.155-0.126
TTM1.155YOY1.739-0.584
TTM1.1555Y7.314-6.159
5Y7.31410Y6.360+0.954
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.8911.843-0.952
MRQ1.0292.249-1.220
TTM1.1552.301-1.146
YOY1.7392.412-0.673
5Y7.3143.782+3.532
10Y6.3604.212+2.148
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of BioNTech SE.

3.1. Institutions holding BioNTech SE

Institutions are holding 18.573% of the shares of BioNTech SE.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-03-31Baillie Gifford & Co Limited.3.46860.59988358939-330243-3.8006
2024-03-31PRIMECAP Management Company1.99510.33084807918444650.9335
2024-03-31Harding Loevner L.P.1.58442.1743818163-126311-3.2022
2024-03-31Flossbach von Storch AG1.43951.39243468986-79674-2.2452
2024-03-31Temasek Holdings Ltd.1.42341.75193430250-1087830-24.0773
2024-03-31BlackRock Inc0.79130.0041190684126682516.2697
2024-03-31Morgan Stanley - Brokerage Accounts0.44980.008108391045565972.5282
2024-03-31Capital World Investors0.39130.014494311643690.4654
2024-03-31FMR Inc0.34620.0052834390697426509.2039
2024-03-31Quinn Opportunity Partners LLC0.2967.2812713383388005.7517
2024-03-31Altrinsic Global Advisors LLC0.29572.9657712708-41680-5.525
2024-03-31VOLORIDGE INVESTMENT MANAGEMENT, LLC0.24850.20185987676825312.8654
2024-03-31Deutsche Bank AG0.20640.0213497468-39385-7.3363
2024-03-31DekaBank Deutsche Girozentrale0.17090.0713411897-13174-3.0992
2024-03-31ClearBridge Advisors, LLC0.15010.0265361813-144879-28.5931
2024-03-31Squarepoint Ops LLC0.13840.053333611173125.4733
2024-03-31Gilder Gagnon Howe & CO LLC0.1140.3167274748-84960-23.6192
2024-03-31Amundi0.11030.0098265812187967.6092
2024-03-31BAMCO Inc0.10420.061825122388753.6621
2024-03-31Mitsubishi UFJ Trust & Banking Corp0.090.0459216950-20130-8.4908
Total 13.814117.335633290893-347486-1.0%

3.2. Funds holding BioNTech SE

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29Performer (AFRIS)12.55720.032130261592302615920
2024-03-31Vanguard Capital Opportunity Inv0.97810.96192357016-720-0.0305
2024-02-29AF High Growth (AFRIS)0.95420.0296229950522995050
2024-02-29FvS SICAV Multiple Opportunities F0.87970.7083212011200
2024-03-31Harding Loevner International Eq Instl0.76981.17281855233-35504-1.8778
2024-05-30iShares Biotechnology ETF0.61442.07241480672-5600-0.3768
2024-03-31PRIMECAP Odyssey Aggressive Growth0.56551.7435136279210400.0764
2024-02-29Global Balanced (AFRIS)0.43770.0651105489110548910
2024-02-29FvS Multiple Opportunities II I0.42630.7256102726400
2024-03-31Capital Group New Perspective Comp0.33180.0542799519-481-0.0601
2024-03-31American Funds New Perspective A0.33180.0542799519-481-0.0601
2024-04-30Baillie Gifford WW L/T Glb Gr B USD Acc0.2741.553866033299751.5338
2024-03-31PRIMECAP Odyssey Growth0.18170.5916437900192004.5856
2024-04-30Baillie Gifford L/T Glb Gr Invm B Acc0.17561.5263423232-5754-1.3413
2024-05-30First Trust NYSE Arca Biotech ETF0.17483.749342129300
2024-03-31Harding Loevner International Equity K0.14181.1894341665-26755-7.2621
2023-11-30Deka-GlobalChampions CF0.14110.488340000200000142.8571
2024-02-29AF Global Equity (AFRIS)0.12520.15943016663016660
2024-04-30ACATIS Datini Valueflex Fonds A0.11623.00528000027761.0014
2024-03-31Baron Focused Growth Retail0.08921.4325215000150007.5
Total 20.266121.31548839203+34090350+69.8%
3rd party ad coffee SUPPORTERis ad-free.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of BioNTech SE compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.9140.037-2598%5.805-116%4.209-122%3.896-123%
Book Value Per Share--89.61289.6580%81.376+10%44.516+101%38.997+130%
Current Ratio--11.37910.437+9%7.726+47%5.755+98%5.320+114%
Debt To Asset Ratio--0.1030.108-5%0.154-33%0.276-63%0.286-64%
Debt To Equity Ratio--0.1150.121-6%0.185-38%0.429-73%0.474-76%
Dividend Per Share----0%0.532-100%0.409-100%0.355-100%
Eps---1.4140.519-373%3.985-135%3.792-137%3.275-143%
Free Cash Flow Per Share---2.0385.544-137%8.919-123%3.806-154%3.293-162%
Free Cash Flow To Equity Per Share---2.0734.989-142%7.020-130%3.637-157%3.174-165%
Gross Profit Margin--1.0501.004+5%0.988+6%1.002+5%1.038+1%
Intrinsic Value_10Y_max--192.986--------
Intrinsic Value_10Y_min--169.770--------
Intrinsic Value_1Y_max--25.337--------
Intrinsic Value_1Y_min--24.891--------
Intrinsic Value_3Y_max--71.557--------
Intrinsic Value_3Y_min--68.406--------
Intrinsic Value_5Y_max--112.265--------
Intrinsic Value_5Y_min--104.595--------
Market Cap19245461400.000-16%22231327500.00024987502450.350-11%35156043394.688-37%29203278620.624-24%25394155322.282-12%
Net Profit Margin---1.680-0.582-65%0.491-442%-0.439-74%-0.500-70%
Operating Margin---1.744-0.927-47%0.666-362%-0.409-77%-0.469-73%
Operating Ratio--3.7042.392+55%0.354+946%1.514+145%1.568+136%
Pb Ratio0.891-16%1.0291.155-11%1.739-41%7.314-86%6.360-84%
Pe Ratio-14.119+13%-16.30917.925-191%26.736-161%3.045-636%2.648-716%
Price Per Share79.860-16%92.250103.590-11%139.693-34%115.866-20%100.753-8%
Price To Free Cash Flow Ratio-9.795+13%-11.3142.065-648%1.717-759%-17.043+51%-14.820+31%
Price To Total Gains Ratio-87.390+13%-100.948-365.054+262%37.814-367%-67.958-33%-67.958-33%
Quick Ratio--15.11912.200+24%7.579+99%6.061+149%5.486+176%
Return On Assets---0.0140.001-1384%0.070-120%0.057-125%0.048-129%
Return On Equity---0.0160.001-1279%0.084-119%0.081-120%0.069-123%
Total Gains Per Share---0.9140.037-2598%6.337-114%4.618-120%4.252-121%
Usd Book Value--21595608300.00021626593275.0000%20418152212.500+6%11067399388.500+95%9693201383.627+123%
Usd Book Value Change Per Share---0.9140.037-2598%5.805-116%4.209-122%3.896-123%
Usd Book Value Per Share--89.61289.6580%81.376+10%44.516+101%38.997+130%
Usd Dividend Per Share----0%0.532-100%0.409-100%0.355-100%
Usd Eps---1.4140.519-373%3.985-135%3.792-137%3.275-143%
Usd Free Cash Flow---491217300.0001336706962.500-137%2296159687.500-121%965667726.975-151%835888434.652-159%
Usd Free Cash Flow Per Share---2.0385.544-137%8.919-123%3.806-154%3.293-162%
Usd Free Cash Flow To Equity Per Share---2.0734.989-142%7.020-130%3.637-157%3.174-165%
Usd Market Cap19245461400.000-16%22231327500.00024987502450.350-11%35156043394.688-37%29203278620.624-24%25394155322.282-12%
Usd Price Per Share79.860-16%92.250103.590-11%139.693-34%115.866-20%100.753-8%
Usd Profit---340780650.00030552375.000-1215%1686545175.000-120%1093336368.600-131%947650644.652-136%
Usd Revenue--202889400.000738015600.000-73%3302089875.000-94%2209432039.500-91%1926433160.217-89%
Usd Total Gains Per Share---0.9140.037-2598%6.337-114%4.618-120%4.252-121%
 EOD+3 -5MRQTTM+10 -24YOY+12 -245Y+11 -2510Y+11 -25

4.2. Fundamental Score

Let's check the fundamental score of BioNTech SE based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-14.119
Price to Book Ratio (EOD)Between0-10.891
Net Profit Margin (MRQ)Greater than0-1.680
Operating Margin (MRQ)Greater than0-1.744
Quick Ratio (MRQ)Greater than115.119
Current Ratio (MRQ)Greater than111.379
Debt to Asset Ratio (MRQ)Less than10.103
Debt to Equity Ratio (MRQ)Less than10.115
Return on Equity (MRQ)Greater than0.15-0.016
Return on Assets (MRQ)Greater than0.05-0.014
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of BioNTech SE based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.301
Ma 20Greater thanMa 5089.218
Ma 50Greater thanMa 10091.545
Ma 100Greater thanMa 20091.348
OpenGreater thanClose79.650
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-03-312023-06-302023-09-302023-12-312024-03-31
Other Stockholders Equity  1,665,834-134,8631,530,971-214,1371,316,8341,0821,317,916-1,329,596-11,680
Accumulated Other Comprehensive Income  -928,792-47,262-976,054-2,487-978,541-86,304-1,064,8451,370,044305,199



Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets22,256,800
Total Liabilities2,288,600
Total Stockholder Equity19,968,200
 As reported
Total Liabilities 2,288,600
Total Stockholder Equity+ 19,968,200
Total Assets = 22,256,800

Assets

Total Assets22,256,800
Total Current Assets18,274,100
Long-term Assets3,982,700
Total Current Assets
Cash And Cash Equivalents 8,976,600
Short-term Investments 6,689,900
Net Receivables 1,925,200
Inventory 345,400
Other Current Assets 337,000
Total Current Assets  (as reported)18,274,100
Total Current Assets  (calculated)18,274,100
+/-0
Long-term Assets
Property Plant Equipment 1,030,900
Goodwill 368,700
Long Term Investments 1,587,200
Intangible Assets 821,700
Long-term Assets Other 83,200
Long-term Assets  (as reported)3,982,700
Long-term Assets  (calculated)3,891,700
+/- 91,000

Liabilities & Shareholders' Equity

Total Current Liabilities1,606,000
Long-term Liabilities682,600
Total Stockholder Equity19,968,200
Total Current Liabilities
Short-term Debt 31,300
Short Long Term Debt 31,300
Accounts payable 298,800
Other Current Liabilities 914,600
Total Current Liabilities  (as reported)1,606,000
Total Current Liabilities  (calculated)1,276,000
+/- 330,000
Long-term Liabilities
Long term Debt 205,000
Long-term Liabilities Other 50,200
Long-term Liabilities  (as reported)682,600
Long-term Liabilities  (calculated)255,200
+/- 427,400
Total Stockholder Equity
Common Stock248,600
Retained Earnings 19,448,200
Accumulated Other Comprehensive Income 282,200
Other Stockholders Equity -10,800
Total Stockholder Equity (as reported)19,968,200
Total Stockholder Equity (calculated)19,968,200
+/-0
Other
Capital Stock248,600
Cash and Short Term Investments 15,666,500
Common Stock Shares Outstanding 240,534
Current Deferred Revenue361,300
Liabilities and Stockholders Equity 22,256,800
Net Debt -8,740,300
Net Invested Capital 20,204,500
Net Working Capital 16,668,100
Property Plant and Equipment Gross 1,030,900
Short Long Term Debt Total 236,300



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-30
> Total Assets 
0
652,986
2,270,306
722,369
738,408
797,647
732,208
973,447
1,449,252
2,318,620
4,204,700
9,148,800
14,232,600
15,830,800
20,299,600
21,155,400
22,660,600
23,279,100
22,079,000
22,225,600
22,207,200
23,006,300
22,256,800
22,256,80023,006,30022,207,20022,225,60022,079,00023,279,10022,660,60021,155,40020,299,60015,830,80014,232,6009,148,8004,204,7002,318,6201,449,252973,447732,208797,647738,408722,3692,270,306652,9860
   > Total Current Assets 
0
448,961
1,585,014
504,322
501,295
560,151
492,855
621,116
1,091,839
1,666,896
3,536,000
8,439,500
13,551,400
15,072,300
19,466,100
20,208,100
21,268,800
21,922,000
20,086,100
19,213,900
18,749,100
19,527,300
18,274,100
18,274,10019,527,30018,749,10019,213,90020,086,10021,922,00021,268,80020,208,10019,466,10015,072,30013,551,4008,439,5003,536,0001,666,8961,091,839621,116492,855560,151501,295504,3221,585,014448,9610
       Cash And Cash Equivalents 
0
411,495
895,370
284,890
463,308
519,149
451,597
573,011
990,461
1,210,209
891,500
914,100
2,392,700
1,692,700
6,164,100
9,334,800
13,423,700
13,875,100
12,143,900
14,166,600
13,495,800
11,663,700
8,976,600
8,976,60011,663,70013,495,80014,166,60012,143,90013,875,10013,423,7009,334,8006,164,1001,692,7002,392,700914,100891,5001,210,209990,461573,011451,597519,149463,308284,890895,370411,4950
       Short-term Investments 
0
336
599,174
190,646
356
1,680
1,723
1,953
17,843
137,234
500
800
1,800
381,600
900
100
4,800
189,400
358,000
1,390,700
2,253,300
4,885,300
6,689,900
6,689,9004,885,3002,253,3001,390,700358,000189,4004,800100900381,6001,800800500137,23417,8431,9531,7231,680356190,646599,1743360
       Net Receivables 
0
28,440
29,291
9,320
9,477
20,205
12,481
10,312
7,894
166,366
2,396,000
7,052,600
10,604,800
12,382,100
12,696,200
10,383,300
7,309,800
7,146,000
6,988,800
2,995,400
2,298,100
2,339,700
1,925,200
1,925,2002,339,7002,298,1002,995,4006,988,8007,146,0007,309,80010,383,30012,696,20012,382,10010,604,8007,052,6002,396,000166,3667,89410,31212,48120,2059,4779,32029,29128,4400
       Other Current Assets 
0
398
38,302
7,477
9,345
1,182
9,263
16,329
54,146
60,966
69,600
113,100
109,300
64,900
64,900
46,600
162,700
271,900
171,300
212,300
286,200
280,900
337,000
337,000280,900286,200212,300171,300271,900162,70046,60064,90064,900109,300113,10069,60060,96654,14616,3299,2631,1829,3457,47738,3023980
   > Long-term Assets 
0
204,025
0
218,047
237,113
237,496
239,353
352,331
357,413
651,724
668,700
709,300
681,200
758,500
833,500
947,300
1,391,800
1,357,100
1,992,900
3,011,700
3,458,100
3,479,000
3,982,700
3,982,7003,479,0003,458,1003,011,7001,992,9001,357,1001,391,800947,300833,500758,500681,200709,300668,700651,724357,413352,331239,353237,496237,113218,0470204,0250
       Property Plant Equipment 
0
115,965
123,054
123,054
142,631
148,060
145,421
167,734
183,503
325,956
360,800
381,100
442,100
520,400
556,900
664,100
760,500
821,100
847,600
894,000
925,900
971,600
1,030,900
1,030,900971,600925,900894,000847,600821,100760,500664,100556,900520,400442,100381,100360,800325,956183,503167,734145,421148,060142,631123,054123,054115,9650
       Goodwill 
0
534
0
0
0
2,978
0
0
0
53,697
0
0
0
57,800
0
0
0
61,200
0
0
365,600
362,500
368,700
368,700362,500365,6000061,20000057,80000053,6970002,9780005340
       Long Term Investments 
0
21
3
1
0
0
0
0
0
0
0
0
0
21,300
48,400
51,500
52,800
80,200
516,800
1,374,300
1,292,700
1,176,100
1,587,200
1,587,2001,176,1001,292,7001,374,300516,80080,20052,80051,50048,40021,30000000000013210
       Intangible Assets 
0
87,508
298,547
94,992
223,506
86,456
93,932
183,281
168,733
109,793
0
0
0
144,600
0
221,400
226,200
158,500
378,600
501,400
665,500
804,100
821,700
821,700804,100665,500501,400378,600158,500226,200221,4000144,600000109,793168,733183,28193,93286,456223,50694,992298,54787,5080
       Other Assets 
0
1,716
0
0
0
2,403
0
1,316
5,177
168,231
142,700
164,100
76,200
22,200
12,200
10,300
352,300
249,200
0
242,000
208,400
0
0
00208,400242,0000249,200352,30010,30012,20022,20076,200164,100142,700168,2315,1771,31602,4030001,7160
> Total Liabilities 
0
385,986
1,061,907
337,879
322,003
304,155
284,078
371,513
521,569
946,774
1,685,100
3,666,000
5,521,100
3,937,100
4,388,900
4,324,700
4,294,300
3,223,500
1,813,700
2,319,100
2,340,400
2,760,400
2,288,600
2,288,6002,760,4002,340,4002,319,1001,813,7003,223,5004,294,3004,324,7004,388,9003,937,1005,521,1003,666,0001,685,100946,774521,569371,513284,078304,155322,003337,8791,061,907385,9860
   > Total Current Liabilities 
0
126,121
427,407
135,993
128,123
138,142
142,043
208,566
268,480
606,014
1,311,100
3,163,300
4,902,600
3,481,600
3,854,500
3,923,700
3,957,700
2,950,600
1,550,900
1,819,000
1,807,200
2,070,500
1,606,000
1,606,0002,070,5001,807,2001,819,0001,550,9002,950,6003,957,7003,923,7003,854,5003,481,6004,902,6003,163,3001,311,100606,014268,480208,566142,043138,142128,123135,993427,407126,1210
       Short-term Debt 
0
6,243
0
867
1,148
7,622
1,107
983
967
9,142
18,000
13,900
19,000
129,900
30,600
32,300
37,000
36,000
37,400
38,600
40,000
28,100
31,300
31,30028,10040,00038,60037,40036,00037,00032,30030,600129,90019,00013,90018,0009,1429679831,1077,6221,14886706,2430
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
9,142
18,000
13,900
19,000
129,900
30,600
32,300
37,000
36,000
37,400
38,600
40,000
28,100
31,300
31,30028,10040,00038,60037,40036,00037,00032,30030,600129,90019,00013,90018,0009,142000000000
       Accounts payable 
0
41,721
53,055
16,881
21,813
20,498
19,417
35,690
41,912
102,288
106,200
262,700
258,900
160,000
123,700
291,100
296,500
204,100
29,900
228,600
222,700
354,000
298,800
298,800354,000222,700228,60029,900204,100296,500291,100123,700160,000258,900262,700106,200102,28841,91235,69019,41720,49821,81316,88153,05541,7210
       Other Current Liabilities 
0
12,130
374,353
29,013
22,577
16,439
26,695
54,232
155,351
103,050
888,500
2,642,600
4,337,400
3,002,600
3,505,200
2,941,000
2,947,300
2,633,400
1,461,600
1,350,600
1,377,400
1,335,100
914,600
914,6001,335,1001,377,4001,350,6001,461,6002,633,4002,947,3002,941,0003,505,2003,002,6004,337,4002,642,600888,500103,050155,35154,23226,69516,43922,57729,013374,35312,1300
   > Long-term Liabilities 
0
259,865
0
201,886
193,880
166,013
142,035
162,947
253,089
340,760
374,000
502,700
618,500
455,500
534,400
401,000
336,600
272,900
262,800
500,100
533,200
689,900
682,600
682,600689,900533,200500,100262,800272,900336,600401,000534,400455,500618,500502,700374,000340,760253,089162,947142,035166,013193,880201,8860259,8650
       Long term Debt Total 
0
0
0
61,333
0
0
66,641
70,289
175,621
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000175,62170,28966,6410061,333000
       Other Liabilities 
0
235,888
190,286
190,286
126,067
97,109
75,394
92,658
92,494
109,713
137,400
259,800
350,800
283,900
379,000
194,400
99,600
0
0
0
371,300
0
0
00371,30000099,600194,400379,000283,900350,800259,800137,400109,71392,49492,65875,39497,109126,067190,286190,286235,8880
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
13,600
11,400
9,400
7,500
0
0
0
0
0
0
0000007,5009,40011,40013,6000000000000000
> Total Stockholder Equity
0
266,153
1,208,399
384,490
416,405
493,492
448,130
601,934
927,683
1,371,846
2,519,600
5,482,800
8,711,500
11,893,700
15,910,700
16,830,700
18,366,300
20,055,600
20,265,300
19,906,500
19,866,800
20,245,900
19,968,200
19,968,20020,245,90019,866,80019,906,50020,265,30020,055,60018,366,30016,830,70015,910,70011,893,7008,711,5005,482,8002,519,6001,371,846927,683601,934448,130493,492416,405384,4901,208,399266,1530
   Common Stock
0
193,296
212,749
212,749
221,787
232,304
232,304
238,198
246,310
246,310
246,300
246,300
246,300
246,300
246,800
248,600
248,600
248,600
248,600
248,600
248,600
248,600
248,600
248,600248,600248,600248,600248,600248,600248,600248,600246,800246,300246,300246,300246,300246,310246,310238,198232,304232,304221,787212,749212,749193,2960
   Retained Earnings Total Equity00000000000000000000000
   Accumulated Other Comprehensive Income 
0
318,628
0
508,242
566,747
691,540
699,564
935,770
1,463,439
1,539,954
1,559,600
1,734,600
1,752,300
1,768,300
2,086,000
1,818,600
1,573,700
979,300
-858,800
-902,500
-904,800
-984,600
282,200
282,200-984,600-904,800-902,500-858,800979,3001,573,7001,818,6002,086,0001,768,3001,752,3001,734,6001,559,6001,539,9541,463,439935,770699,564691,540566,747508,2420318,6280
   Capital Surplus 00000000000000000000000
   Treasury Stock00000000000000-5,525-5,525-5,525000000
   Other Stockholders Equity 
0
365,483
508,242
508,242
-5,525
-5,525
-5,525
-5,525
-5,525
-4,789
-4,800
-3,800
-3,800
-3,800
-3,800
-5,900
-10,300
-5,300
1,540,300
1,415,600
1,217,600
1,218,600
-10,800
-10,8001,218,6001,217,6001,415,6001,540,300-5,300-10,300-5,900-3,800-3,800-3,800-3,800-4,800-4,789-5,525-5,525-5,525-5,525-5,525508,242508,242365,4830



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue3,819,000
Cost of Revenue-599,800
Gross Profit3,219,2003,219,200
 
Operating Income (+$)
Gross Profit3,219,200
Operating Expense-2,315,000
Operating Income690,400904,200
 
Operating Expense (+$)
Research Development1,783,100
Selling General Administrative495,000
Selling And Marketing Expenses62,700
Operating Expense2,315,0002,340,800
 
Net Interest Income (+$)
Interest Income357,600
Interest Expense-7,738
Other Finance Cost-162
Net Interest Income349,700
 
Pretax Income (+$)
Operating Income690,400
Net Interest Income349,700
Other Non-Operating Income Expenses0
Income Before Tax (EBT)1,186,100758,200
EBIT - interestExpense = 964,262
1,186,100
938,038
Interest Expense7,738
Earnings Before Interest and Taxes (EBIT)972,0001,193,838
Earnings Before Interest and Taxes (EBITDA)1,155,400
 
After tax Income (+$)
Income Before Tax1,186,100
Tax Provision-255,800
Net Income From Continuing Ops930,300930,300
Net Income930,300
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses2,914,800
Total Other Income/Expenses Net-67,800-349,700
 

Technical Analysis of Biontech
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Biontech. The general trend of Biontech is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Biontech's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of BioNTech SE.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 90.24 < 104.33 < 113.04.

The bearish price targets are: .

Tweet this
BioNTech SE Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of BioNTech SE. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

BioNTech SE Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of BioNTech SE. The current macd is -4.24024683.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Biontech price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Biontech. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Biontech price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
BioNTech SE Daily Moving Average Convergence/Divergence (MACD) ChartBioNTech SE Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of BioNTech SE. The current adx is 28.69.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Biontech shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
BioNTech SE Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of BioNTech SE. The current sar is 86.06.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
BioNTech SE Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of BioNTech SE. The current rsi is 31.30. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
BioNTech SE Daily Relative Strength Index (RSI) ChartBioNTech SE Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of BioNTech SE. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Biontech price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
BioNTech SE Daily Stochastic Oscillator ChartBioNTech SE Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of BioNTech SE. The current cci is -84.13292587.

BioNTech SE Daily Commodity Channel Index (CCI) ChartBioNTech SE Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of BioNTech SE. The current cmo is -46.72392031.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
BioNTech SE Daily Chande Momentum Oscillator (CMO) ChartBioNTech SE Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of BioNTech SE. The current willr is -90.91806515.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
BioNTech SE Daily Williams %R ChartBioNTech SE Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of BioNTech SE.

BioNTech SE Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of BioNTech SE. The current atr is 2.88290301.

BioNTech SE Daily Average True Range (ATR) ChartBioNTech SE Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of BioNTech SE. The current obv is -26,974,023.

BioNTech SE Daily On-Balance Volume (OBV) ChartBioNTech SE Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of BioNTech SE. The current mfi is 15.43.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -2/(-2 +2).

  • MFI < 50: -1
  • MFI < 20: -1
BioNTech SE Daily Money Flow Index (MFI) ChartBioNTech SE Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for BioNTech SE.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-02-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-20CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-29SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-25CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-04-05STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-19STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-25DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-05-01DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-05-02DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-05-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-08MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-05-09STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-05-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-05-17STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-05-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-05-23RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-05-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-05-28SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-05-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-05-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-06-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-06-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-05STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-06-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-11MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-06-12CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-06-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-06-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-06-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-06-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-06-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-06-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-06-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-07-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-07-03RSI LONG ENTRY SHORT CLOSE30 crossover to upside

6.3. Candlestick Patterns

BioNTech SE Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of BioNTech SE based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.301
Ma 20Greater thanMa 5089.218
Ma 50Greater thanMa 10091.545
Ma 100Greater thanMa 20091.348
OpenGreater thanClose79.650
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Biontech with someone you think should read this too:
  • Are you bullish or bearish on Biontech? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Biontech? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about BioNTech SE

I send you an email if I find something interesting about BioNTech SE.


Stay informed about BioNTech SE.

Receive notifications about BioNTech SE in your mailbox!